Zealand Pharma wraps up patient enrollment in SBS trial

Denmark’s Zealand Pharma has finished enrolling patients in a phase II trial with candidate glepaglutide for the treatment of short bowel syndrome. The first data are expected later this year.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us free for 14 days

Get 14 days free trial access

Frontpage right now

Latest Top picks in English

Related articles